Paromomycin Alone topical cream — Competitive Intelligence Brief

Paromomycin Alone topical cream (Paromomycin Alone topical cream) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aminoglycoside antibiotic. Area: Dermatology / Infectious Disease.

phase 3 Aminoglycoside antibiotic Bacterial 30S ribosomal subunit Dermatology / Infectious Disease Small molecule

Target snapshot

Paromomycin Alone topical cream (Paromomycin Alone topical cream) — U.S. Army Medical Research and Development Command. Paromomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and when applied topically as a cream, it kills or inhibits the growth of susceptible microorganisms on the skin surface.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Paromomycin Alone topical cream TARGET	Paromomycin Alone topical cream	U.S. Army Medical Research and Development Command	phase 3	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Tigecycline antimicrobial-lock solution	Tigecycline antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Neomycin Oral Product	Neomycin Oral Product	South Australian Health and Medical Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
topical tetracycline	topical tetracycline	Johns Hopkins University	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Doxycycline post-exposure prophylaxis	Doxycycline post-exposure prophylaxis	University of Washington	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Tetracyclin ointment	Tetracyclin ointment	University of Oslo	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Aerosolized Tobramycin or Vancomycin	Aerosolized Tobramycin or Vancomycin	Wright State University	marketed	Aminoglycoside antibiotic (tobramycin) / Glycopeptide antibiotic (vancomycin)	Bacterial 30S ribosomal subunit (tobramycin) / Bacterial cell wall peptidoglycan (vancomycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aminoglycoside antibiotic class)

1. U.S. Army Medical Research and Development Command · 2 drugs in this class
2. Hospital General Universitario Elche · 2 drugs in this class
3. Murdoch Childrens Research Institute · 2 drugs in this class
4. Public Health Service of Amsterdam · 1 drug in this class
5. Seattle Children's Hospital · 1 drug in this class
6. Shanghai Pulmonary Hospital, Shanghai, China · 1 drug in this class
7. Shanghai Zhongshan Hospital · 1 drug in this class
8. South Australian Health and Medical Research Institute · 1 drug in this class
9. The University of Queensland · 1 drug in this class
10. University of Leipzig · 1 drug in this class